Stock screenerAll disclosures →
EDGAR →
CLDX
Conviction 33HealthcareScan · Thu, Sep 24, 2026Celldex Therapeutics, Inc. (CLDX) closed at $31.47 (+1.12%) on Sep 24, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 26, RS Rating 72, -29.9% from its 52-week high, +16.5% year to date. Sector: Healthcare · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES.
CLDX$31.47+1.12%
ResistanceSupportVol 14Vol MA14 2.11M
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
Price31.47
Change+1.12%
Gap-0.39%
Rel volume1.32×
Avg volume1.63M
Avg $ vol57.4M
SMA 2037.87
SMA 5038.72
SMA 20032.23
Price vs 50-18.72%
Price vs 200-2.35%
MA stackmixed
50/200 cross—
Supertrenddown · 38.10
RSI (14)26
MACD hist-0.86
MACD cross—
Stoch %K / %D10 / 15
ADX (14)17
+DI / −DI18 / 33
RSI divergence—
MACD divergenceBullish
ATR %6.79%
ADR %5.13%
52w high44.87
52w low22.58
From 52w high-29.86%
Above 52w low+39.37%
New 52w highNo
SqueezeOff
Bollinger width27.39%
%B-0.12
Donchian pos9.62%
Donchian high41.62
Donchian low30.39
AVWAP (52w high)37.02
vs AVWAP high-15.00%
AVWAP (52w low)32.20
vs AVWAP low-2.25%
OBV trendDown
Chaikin MF (20)-0.20
Today vs 20d1.32×
Avg vol (14d)2.11M
Avg vol (20d)1.63M
Avg $ vol (20d)57.4M
Market cap2.47B
RS Rating72 / 99
RS 3m (vs SPY)-12.18%
RS 6m (vs SPY)-17.48%
RS line new highNo
Trend template4/8
Technical rank27.9
1 week-19.27%
1 month-23.65%
3 months-7.69%
6 months-0.66%
1 year+29.88%
YTD+16.51%
P/E-9.55
P/B3.46
P/S—
P/FCF-11.57
EPS-3.90
Div yield—
ROE-36.21%
ROA-33.07%
Debt/Eq—
Current11.82
EV/EBITDA-8.54
Gross margin—
Net margin—
Rev growth-77.99%
EPS growth-63.91%
Price target64.58
Target upside105.21%
Analyst ratingBuy
Institutional113.57%
Ent. value2.42B
Revenue22K
Net income-73.5M
Gross profit—
Free cash flow-213.66M
IndustryIN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
ExchangeNasdaq
Shares out78.49M
Employees198
ListedThu, May 15, 1986
Free float70.91M
Float %90.3%
Short interest8.64M
Days to cover12.2d
Short volume67.0%
Squeeze score72 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.94 vs −$1.04
Last surprise+9.6% beat
Setup gradeD
Conviction33 / 100
Pattern quality—
Tech rank27.9 / 100
Group rank59 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance44.17
Support33.62
Days since event—
Candle confirm—
Financials as of Tue, Jun 30, 2026 · quarterly.
Recent news
- Celldex Therapeutics Leads Guggenheim’s Biotechnology Rankings By Investing.comInvesting.com UK · Wed, Sep 23, 2026
- Leerink Partners maintains Outperform rating on Celldex Therapeutics, $88 price targetTradingView · Wed, Sep 23, 2026
- Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success?Yahoo Finance · Wed, Sep 23, 2026
- The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and VaxcyteYahoo Finance · Wed, Sep 23, 2026
- Market Movers | Winners: VKTX, INDP, MAZE | Losers: XNDU, EVER, CLDXTrefis · Wed, Sep 23, 2026
- Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria - Slideshow (NASDAQ:CLDX) 2026-09-22Seeking Alpha · Tue, Sep 22, 2026
- Why is Celldex Therapeutics stock sliding today?Investing.com India · Tue, Sep 22, 2026
- Why is Celldex Therapeutics stock sliding today? By Investing.comInvesting.com UK · Tue, Sep 22, 2026
- CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’Stocktwits · Tue, Sep 22, 2026
- Celldex Therapeutics Shares Fall After Phase 3 Readout Despite Positive Trial Results | CLDX Stock NewsQuiver Quantitative · Tue, Sep 22, 2026
Congress activity
Disclosed STOCK Act trades in CLDX
No recent disclosed trades by Congress in CLDX. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in CLDX
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Jain Rita Director · Non-Qualified Stock Option (right to buy) · 2026-06-25 | Grant | 26K | — | 2026-06-25 | 2026-06-29 |
Torres Denice Director · Non-Qualified Stock Option (right to buy) · 2026-06-25 | Grant | 26K | — | 2026-06-25 | 2026-06-29 |
KELER TIBOR EXECUTIVE VP & CSO · Incentive Stock Option (right to buy) · 2026-06-25 | Grant | 115K | — | 2026-06-25 | 2026-06-29 |
CONRAD HERBERT J Director · Non-Qualified Stock Option (right to buy) · 2026-06-25 | Grant | 26K | — | 2026-06-25 | 2026-06-29 |
Martin Samuel Bates SVP AND CFO · Incentive Stock Option (right to buy) · 2026-06-25 | Grant | 93K | — | 2026-06-25 | 2026-06-29 |
Heath-Chiozzi Margo SVP OF REGULATORY AFFAIRS · Incentive Stock Option (right to buy) · 2026-06-25 | Grant | 95K | — | 2026-06-25 | 2026-06-29 |
Brownlie Keith L Director · Non-Qualified Stock Option (right to buy) · 2026-06-25 | Grant | 26K | — | 2026-06-25 | 2026-06-29 |
Cavanaugh Sarah SVP OF CORP AFFAIRS & ADMIN. · Incentive Stock Option (right to buy) · 2026-06-25 | Grant | 95K | — | 2026-06-25 | 2026-06-29 |
PENNER HARRY JR Director · Non-Qualified Stock Option (right to buy) · 2026-06-25 | Grant | 26K | — | 2026-06-25 | 2026-06-29 |
MARINO JAMES J Director · Non-Qualified Stock Option (right to buy) · 2026-06-25 | Grant | 26K | — | 2026-06-25 | 2026-06-29 |
SEC filings
EDGAR filings in CLDX · 7 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.